Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome.
Intravenous immunoglobulin (IVIg) therapy has shown promise in the treatment of Alzheimer's disease (AD). In this study, serial cerebrospinal fluid (CSF) samples from a group of subjects with AD undergoing IVIg immunotherapy are analyzed to identify IVIg-related changes. CSF samples from eight subjects were collected before therapy, after 6 months of therapy, and after a 3-month drug washout period. Samples were analyzed using a gel-based proteomics strategy and IVIg-related changes were determined by gel spot percent volumes. An initial assessment of the data revealed consistent and considerable change in 69 spots. A statistical analysis revealed 79 protein spots with a significant change after 6 months; furthermore, in a subset of these (25), the percent volume change was either maintained or reversed in the washout samples. The proteins that showed a significant change during IVIg therapy, including Ig molecules, gelsolin, transferrin, and transthyretin, have been previously implicated in AD. This study provides preliminary findings regarding a group of CSF proteins that may be associated with the treatment of AD, as well as the potential use of IVIg as an AD immunotherapy.
Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Gilda
G
Shayan
Basia
B
Adamiak
Leila H
LH
Choe
Norman
N
Relkin
Kelvin H
KH
Lee
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002556:Cerebrospinal Fluid Proteins / Q000134:cerebrospinal fluid* / Q000737:chemistry; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D020543:Proteome / Q000032:analysis*; D040901:Proteomics
D015415:Biomarkers; D002556:Cerebrospinal Fluid Proteins; D016756:Immunoglobulins, Intravenous; D020543:Proteome
Alzheimer's disease; Biomarker; Cerebrospinal fluid; Intravenous immunoglobulin